Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1192 Articles

Paul Ausick | Apr 15, 2014 at 4:01 PM EDT

The 4 Stocks That Pulled the Markets Out of the Doldrums

thinkstockApril 15, 2014: Markets opened slightly higher on Tuesday with shares moving up before bouncing down after headlines related to…

Paul Ausick | Apr 15, 2014 at 8:30 AM EDT

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for…

Paul Ausick | Apr 12, 2014 at 11:02 AM EDT

And Then There Were Three: ADP Loses Triple-A Rating

ThinkstockWhen Automatic Data Processing Inc. (NYSE: ADP) announced on Thursday that it would spin off its dealer services business, it…

Jon C. Ogg | Apr 8, 2014 at 8:10 AM EDT

Highest Yielding UBS Dividend Ruler Stocks

ThinkstockThe more the market gets hit, the more people stare at their portfolios and wonder what would be the best…

Douglas A. McIntyre | Mar 30, 2014 at 10:08 AM EDT

Coca-Cola Tops Powerful Brands List

courtesy of The Coca-Cola CompanyOne of the world’s most recognized brand — The Coca-Cola Co. (NYSE: KO) — topped a new…

Trey Thoelcke | Mar 14, 2014 at 8:50 AM EDT

Jefferies’ Cheapest Health Care Stocks to Buy

In a new report out from Jefferies, the analysts posted a complete list of the cheapest, on a P/E basis,…

cgblaine22 | Mar 3, 2014 at 10:55 AM EST

Dendreon Finds New, Long Overdue Lifeblood

Shares of Dendreon moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug,…

cgblaine22 | Feb 26, 2014 at 10:15 AM EST

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

Shares of biotechnology company Anika Therapeutics soared to an all-time high Wednesday after the company said the FDA had approved…

Jon C. Ogg | Feb 14, 2014 at 5:06 PM EST

Meet the 2014 Warren Buffett and Berkshire Hathaway Stocks

White House Photo by Pete SouzaAs many consider Warren Buffett to be the greatest investor of modern times, investors want…

Trey Thoelcke | Feb 12, 2014 at 8:00 AM EST

UBS Adds Three Top Names to the Dividend Ruler Stock List

The UBS team thinks that investors that take "flight to safety" into U.S. treasury bonds and defensive, high dividend yield…

Jon C. Ogg | Feb 4, 2014 at 9:20 AM EST

Merrill Lynch’s Top Dividend and Yield Stocks to Buy During the Pullback

The top equity strategist at Merrill Lynch has updated the High Quality and Dividend Yield screen of stocks to buy,…

Jon C. Ogg | Jan 21, 2014 at 8:05 AM EST

An Earnings Beat by J&J Meets Tempered 2014 Guidance

Wikimedia CommonsJohnson & Johnson (NYSE: JNJ) is out with its fourth-quarter earnings report. The pharma and consumer products giant is…

Jon C. Ogg | Jan 11, 2014 at 10:21 AM EST

Boeing and the Johnsons Tie For Best DJIA Stock of the Week

Frank Golhen, via Wikimedia Commons24/7 Wall St. is rather focused on, and perhaps a bit concerned about, how the Dow…

Jon C. Ogg | Jan 9, 2014 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Bed Bath & Beyond, J.C. Penney and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, January 8, 2014.

Paul Ausick | Jan 7, 2014 at 4:14 PM EST

The 5 Stocks That Moved the Market on Tuesday

thinkstockJanuary 7, 2014: Markets opened higher on Tuesday led by healthcare and tech stocks. The S&P 500 closed with a…

1 … 47 48 49 50 51 … 80

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

The 4 Stocks That Pulled the Markets Out of the Doldrums

Johnson & Johnson Earnings Point to New 52-Week High

And Then There Were Three: ADP Loses Triple-A Rating

Highest Yielding UBS Dividend Ruler Stocks

Coca-Cola Tops Powerful Brands List

Jefferies’ Cheapest Health Care Stocks to Buy

Dendreon Finds New, Long Overdue Lifeblood

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

Meet the 2014 Warren Buffett and Berkshire Hathaway Stocks

UBS Adds Three Top Names to the Dividend Ruler Stock List

Merrill Lynch’s Top Dividend and Yield Stocks to Buy During the Pullback

An Earnings Beat by J&J Meets Tempered 2014 Guidance

Boeing and the Johnsons Tie For Best DJIA Stock of the Week

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Bed Bath & Beyond, J.C. Penney and More

The 5 Stocks That Moved the Market on Tuesday

Here Is the 1 Dirt-Cheap Semiconductor Titan I Keep Loading Up on Repeat

In a Healthy Year, Medicare Advantage Saves You $2,640. In a Cancer Year, It Can Cost $9,250

Buy, Hold, or Sell: Strategy Inc. Resumed Its Bitcoin Buying Spree, but Will Warsh’s First Fed Meeting and Severe Tech Compression Crush MSTR Stock to $65?

In a Healthy Year, Medicare Advantage Saves You $2,640. In a Cancer Year, It Can Cost $9,250

A $60,000 Annuity Payout Pushed a Retired Couple Over the Medicare IRMAA Line Two Years Later

Here Is the 1 Dirt-Cheap Semiconductor Titan I Keep Loading Up on Repeat

In a Healthy Year, Medicare Advantage Saves You $2,640. In a Cancer Year, It Can Cost $9,250

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

The 4 Stocks That Pulled the Markets Out of the Doldrums

Johnson & Johnson Earnings Point to New 52-Week High

And Then There Were Three: ADP Loses Triple-A Rating

Highest Yielding UBS Dividend Ruler Stocks

Coca-Cola Tops Powerful Brands List

Jefferies’ Cheapest Health Care Stocks to Buy

Dendreon Finds New, Long Overdue Lifeblood

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

Meet the 2014 Warren Buffett and Berkshire Hathaway Stocks

UBS Adds Three Top Names to the Dividend Ruler Stock List

Merrill Lynch’s Top Dividend and Yield Stocks to Buy During the Pullback

An Earnings Beat by J&J Meets Tempered 2014 Guidance

Boeing and the Johnsons Tie For Best DJIA Stock of the Week

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Bed Bath & Beyond, J.C. Penney and More

The 5 Stocks That Moved the Market on Tuesday

Here Is the 1 Dirt-Cheap Semiconductor Titan I Keep Loading Up on Repeat

In a Healthy Year, Medicare Advantage Saves You $2,640. In a Cancer Year, It Can Cost $9,250

Buy, Hold, or Sell: Strategy Inc. Resumed Its Bitcoin Buying Spree, but Will Warsh’s First Fed Meeting and Severe Tech Compression Crush MSTR Stock to $65?

Featured Reads

In a Healthy Year, Medicare Advantage Saves You $2,640. In a Cancer Year, It Can Cost $9,250

A $60,000 Annuity Payout Pushed a Retired Couple Over the Medicare IRMAA Line Two Years Later